Biostar pharmaceuticals, inc. (BSPM)
CashFlow / TTM
Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
CASH FLOWS FROM (USED IN) OPERATING ACTIVITIES
Net loss

934

-504

-6,092

-5,698

-32,291

-31,982

-25,572

-25,112

749

2,243

4,381

4,848

2,783

2,931

554

809

-6,525

-12,852

-21,603

-19,997

-12,421

-2,017

11,617

12,173

0

0

0

Adjustments to reconcile net income to net cash provided by operating activities:
Accrued interest income

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred tax benefit

-

-

-

-

-

-

-

1,332

-4,409

-4,191

-4,626

-4,284

-8

9

483

981

203

9

-2,191

-2,036

0

0

0

-

-

-

-

Depreciation and amortization

1,108

1,209

1,123

1,142

2,228

1,855

2,149

2,320

1,622

2,472

2,837

3,086

3,228

3,154

3,063

2,786

2,486

2,138

1,830

1,827

1,857

1,545

1,234

885

0

0

0

Recognition of deferred research and development expenses

-

-

-

-

-

-

-

4,020

2,397

2,404

3,089

2,766

2,199

3,011

3,127

3,228

0

0

0

-

-

-

-

-

-

-

-

Impairment loss on loan receivable

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Provision for doubtful accounts

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

Recognition of deferred research and development expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Stock-based compensation

-

-

-

-

-

-

-

-

-

-

-

2,021

2,098

950

850

757

641

756

784

821

0

0

0

-

-

-

-

Fair value adjustment on warrants

-

-

-

-

-

-

-

324

460

264

567

577

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Fair value adjustment on warrants

0

0

0

-

0

0

0

-

-

-

-

-

0

0

0

-

0

0

0

-

0

0

0

-

-

-

-

Changes in operating assets and liabilities:
Stock-based compensation and other non-cash expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Accounts receivable

-13,944

-13,982

-8,717

-8,669

-11,749

-9,828

-4,170

-5,448

73

1,264

1,522

7,441

17,110

13,591

4,703

-4,204

-18,426

-11,637

-11,370

-6,629

4,947

-1,792

5,191

5,332

0

0

0

Inventories

-272

-147

-114

-55

-186

-170

-83

-420

-86

-158

-341

-152

-469

-1,070

-696

-43

196

871

454

-535

-1,230

-1,235

-213

609

0

0

0

Deposits and other receivables

329

193

21

176

1,927

428

-301

-392

-892

-149

1,061

-244

-1,027

-404

-1,998

161

1,387

1,519

2,634

1,870

-4

-5

56

10

0

0

0

Accounts payable and accrued expenses

-1,412

-1,039

-1,093

-1,087

-3,303

-1,558

-611

-602

2,076

230

-711

573

441

-69

-993

-1,449

1,435

3,022

1,942

3,197

-2,516

-3,407

255

-1,638

0

0

0

Value-added tax payable

0

0

0

-

0

0

0

-

51

47

-257

90

-517

100

-26

-301

48

278

-375

-271

-411

-962

-70

-675

0

0

0

Income tax recoverable

-

-

0

-

-

-

0

-

-

-

-

305

-343

-300

265

-100

-250

187

-874

-1,918

-3,446

-2,287

-541

-528

0

0

0

Exchange difference

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

68

178

259

270

0

0

0

Net cash provided by operating activities

8,587

9,145

4,890

4,912

6,995

5,791

3,385

5,877

3,648

2,713

3,041

3,310

-5,343

-241

5,833

8,909

15,161

3,880

-3,150

-3,583

-8,111

6,570

13,131

8,773

0

0

0

CASH FLOWS USED IN INVESTING ACTIVITIES
Payment for acquisition of Shaanxi Weinan

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

823

0

0

0

-

-

-

-

Deposit paid for intended acquisition

-

-

-

-

-

-

-

8,122

6,504

6,517

6,511

4,881

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Deposit paid to intended acquisition

-

-

-

-

-

-

-

59

2,414

2,420

2,897

2,869

488

506

979

982

978

974

37

32

37

23

25

110

0

0

0

Net cash used in investing activities

-10,786

-10,741

-6,378

-6,378

-5,723

-5,710

-5,717

-7,377

-11,611

-11,630

-10,536

-8,878

420

-2,459

-4,208

-4,210

-21,767

-17,671

-16,470

-17,288

-3,115

-7,449

-7,076

-6,339

0

0

0

CASH FLOWS USED IN FINANCING ACTIVITIES
Repayment to a related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

669

534

334

0

0

0

Proceeds from short-term bank loans

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

787

0

0

0

Repayment of short-term bank loans

-2

-4

-4

278

255

255

280

160

0

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Advance from a related party

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Advance from (repayment to) a related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Proceeds from stock issuance and warrants

-

-

-

-

-

-

-

-

-

-

-

3,862

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from stock issuance and warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

Net cash used in financing activities

1,692

1,694

1,693

1,411

-255

-255

-280

-160

-419

-387

2,820

6,954

2,337

2,298

-895

-6,457

4,728

4,734

3,953

5,545

-786

-1,112

129

787

0

0

0

Effect of exchange rate changes on cash and cash equivalents

212

102

185

188

-468

69

-5

14

695

277

251

218

-167

-206

-54

80

309

298

155

114

126

323

489

539

0

0

0

Net increase in cash and cash equivalents

-294

200

392

134

547

-106

-2,617

-1,646

-7,687

-9,027

-4,423

1,605

-2,752

-610

675

-1,679

-1,568

-8,758

-15,513

-15,212

-11,887

-1,669

6,672

3,760

0

0

0

SUPPLEMENTAL DISCLOSURES:
Interest received

2

2

2

1

3

3

4

8

665

1,335

1,332

1,330

0

0

0

-

-

-

303

296

0

0

0

-

-

-

-

Interest paid

-105

-0

37

37

217

112

72

133

131

214

216

154

249

545

262

355

126

-252

30

-62

0

0

0

-

-

-

-

Income tax payments

-

-

-

-

-

-

-

-

-

-

-

665

973

2,051

869

965

619

-703

-3,858

-2,387

-5,849

-5,765

-7,138

-6,699

0

0

0